Cadrenal Therapeutics, Inc.
CVKD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001937993
In the last 90 days, Cadrenal Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 19 institutions reported holding it in 13F filings for Q2 2026, worth $379.6K in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Cadrenal Therapeutics, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- +1 vs. Q4 2025
- Shares held
- 91.1K
- +23.5K (+34.7%) vs. Q4 2025
- Total value
- $460.1K
- +$1.75K (+0.4%) vs. Q4 2025
- New holders
- 5
- 2 more added
- Sold out
- 4
- 5 more reduced
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CVKD on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 19 | $379.6K |
| Q1 2026 | 20 | $460.1K |
| Q4 2025 | 20 | $823.9K |
| Q3 2025 | 20 | $1.57M |
| Q2 2025 | 17 | $823.9K |
| Q1 2025 | 16 | $1.22M |
| Q4 2024 | 10 | $215.5K |
| Q3 2024 | 2 | $68 |
| Q2 2024 | 9 | $165.0K |
| Q1 2024 | 10 | $1.04M |
| Q4 2023 | 6 | $407.5K |
| Q3 2023 | 9 | $751.9K |
| Q2 2023 | 3 | $429 |
| Q1 2023 | 3 | $1.34K |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Cadrenal Therapeutics, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 45,201 | $231.4K | 0.00% | +45,201 | New |
| Geode Capital Management, LLC | 21,626 | $110.7K | 0.00% | +7,098+48.9% | Added |
| Vanguard Fiduciary Trust Co | 8,311 | $42.6K | 0.00% | +8,311 | New |
| JPMorgan Chase & Co | 7,500 | $31.9K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 5,496 | $28.1K | 0.00% | +1,974+56.0% | Added |
| Cygnus Capital Advisors, LLC | 1,492 | $8.00K | 0.01% | +1,492 | New |
| Tower Research Capital LLC (TRC) | 393 | $2.01K | 0.00% | −139−26.1% | Reduced |
| Advisor Group Holdings, Inc. | 300 | $1.54K | 0.00% | −200−40.0% | Reduced |
| RWM Asset Management, LLC | 200 | $1.02K | 0.00% | +200 | New |
| Rockefeller Capital Management L.P. | 150 | $768 | 0.00% | −150−50.0% | Reduced |
| Morgan Stanley | 100 | $512 | 0.00% | −980−90.7% | Reduced |
| Harbour Investments, Inc. | 100 | $512 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 99 | $507 | 0.00% | 00.0% | Unchanged |
| Archer Investment Corp | 35 | $179 | 0.00% | 00.0% | Unchanged |
| IFP Advisors, Inc | 30 | $154 | 0.00% | 00.0% | Unchanged |
| Farther Finance Advisors, LLC | 25 | $123 | 0.00% | 00.0% | Unchanged |
| Caldwell Sutter Capital, Inc. | 5 | $26 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 3 | $15 | 0.00% | −1,041−99.7% | Reduced |
| Curio Wealth, LLC | 1 | $5 | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 1 | $5 | 0.00% | +1 | New |
| DRW Securities, LLC | 0 | $0 | 0.00% | −25,152−100.0% | Sold out |
| LPL Financial LLC | 0 | $0 | 0.00% | −13,000−100.0% | Sold out |
| Clearstead Advisors, LLC | 0 | $0 | 0.00% | −150−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |